BlueSphere Bio and the National Cancer Institute Team Up to Develop Therapies for Rare Respiratory Disease
Shots:
- BlueSphere has signed a cooperative research & development agreement (CRADA) with the NCI to develop new TCR T-cell therapy for recurrent respiratory papillomatosis (RRP)
- The partnership will prepare & assess TCRs, identified by BlueSphere using the TCXpress platform for HPV 6 & 11 (linked to RRP) under a previous material transfer agreement that granted it access to NCI’s HPV+ tumor samples, for their efficacy in an early-stage RRP trial
- BlueSphere, under the supervision of NCI’s Center for Cancer Research (CCR), will conduct clinical trials (sponsored by either the NCI or BlueSphere) with NCI handling the testing, sequence modifications, process development, manufacturing & trial activities of the TCRs provided by BlueSphere
Ref: BlueSphere Bio | Image: BlueSphere Bio
Related News:- Lupin Launches Smart Device for Metered-Dose Inhalers to Support Treatment of Respiratory Diseases in India
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
